The phase III IMpower010 trial reinforced the significant disease-free survival benefit offered by Tecentriq (atezolizumab) for people with stage II-IIIA non-small cell lung cancer whose tumors express PD-L1≥1%.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
